SAGE Therapeutics Inc. (SAGE)

144.83
4.02 2.85
NASDAQ : Health Technology
Prev Close 140.81
Open 141.52
Day Low/High 140.07 / 145.76
52 Wk Low/High 79.88 / 193.56
Volume 504.03K
Avg Volume 386.20K
Exchange NASDAQ
Shares Outstanding 51.65M
Market Cap 7.45B
EPS -8.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
SAGE Announces Initiation Of Phase 1 And First Dosing Of SAGE-217

SAGE Announces Initiation Of Phase 1 And First Dosing Of SAGE-217

SAGE's First Oral Compound From Its Pipeline of Next Generation CNS Modulators Enters Clinical Development

SAGE Therapeutics Expands Leadership Team With Key Appointments

SAGE Therapeutics Expands Leadership Team With Key Appointments

Strategic Additions Broaden Organizational Capabilities as SAGE Advances Novel Therapeutics in Clinical and Late-Stage Development

Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study

Sage Psychiatric Drug Shows Activity Hint in Small Muscle Tremor Study

The signal of activity Sage Therapeutics sees with SAGE-547 in essential tremor may turn out to be real or a mirage.

SAGE Announces First Patient Treated In Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus

SAGE Announces First Patient Treated In Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus

STATUS Trial of SAGE-547 is First Global Phase 3 Trial of Patients With SRSE, a Rare and Life-Threatening Seizure Disorder With no Approved Therapies

SAGE Receives Special Protocol Assessment For Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus

SAGE Receives Special Protocol Assessment For Phase 3 STATUS Trial Of SAGE-547 In Super-Refractory Status Epilepticus

Provides FDA Agreement on Trial Design, Endpoints and Statistical Approach of the Phase 3 STATUS Trial

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years

Only one fund category (of 20) has beaten the S&P 500 over half a decade.

SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus

SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol To Evaluate SAGE-547 In Patients With Super-Refractory Status Epilepticus

Phase 3 STATUS Trial - Randomized, Double-Blind, Placebo-Controlled Clinical Trial of SAGE-547 for the Treatment of Patients With SRSE - Expected to Initiate by Mid-2015

SAGE Therapeutics Announces Presentations At Upcoming Scientific Conferences

SAGE Therapeutics Announces Presentations At Upcoming Scientific Conferences

Final SAGE-547 Super-Refractory Status Epilepticus Phase 1/2 Clinical Data to be Presented at Antiepileptic Drug and Device Trials Conference

SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA And Planned Initiation Of SAGE-547 Global Phase 3 Trial In Mid-2015

SAGE Therapeutics Announces Positive End-of-Phase 2 Meeting With FDA And Planned Initiation Of SAGE-547 Global Phase 3 Trial In Mid-2015

Final SAGE-547 Phase 1/2 Clinical Data to be Presented at Annual Antiepileptic Drug and Device Trials Conference

SAGE Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

SAGE Therapeutics Reports Fourth Quarter And Full Year 2014 Financial Results

Multiple Clinical and Scientific Milestones Anticipated in 2015

SAGE Therapeutics Appoints New Vice Presidents To Lead Key Organizational Functions

SAGE Therapeutics Appoints New Vice Presidents To Lead Key Organizational Functions

Amy Schacterle, Ph.D. Joins SAGE as Vice President of Regulatory Affairs and Quality Assurance, Erin Lanciani as Vice President of Human Resources

TheStreet Quant Rating: D (Sell)